Studies | EBMT

Top

Study type

Disease

Group

Type of transplant / Cell therapy

Text

Language

Impact of the Addition of Antithymocyte Globulin to Post-Transplantation Cyclophosphamide in Haploidentical Transplantation with Peripheral Blood Compared to Post-Transplantation Cyclophosphamide Alone: A Retrospective Study on Behalf of the CTIWP

Retrospective Studies

Acute Lymphatic Leukaemia (ALL)

Acute Myeloid Leukaemia (AML)

Chronic Lymphocytic Leukaemia (CLL)

Chronic Myeloid Leukaemia (CML)

Chronic Lymphocytic Leukaemia (CLL)

Myelodysplastic (MDS) or MDS/MPN

Cellular Therapy & Immunobiology Working Party (CTIWP)

Type of treatment

Allogeneic - Haploidentical

Principal investigator

Impact of body mass index on outcome of CART cell therapy

Retrospective Studies

Transplant Complications Working Party (TCWP)

Type of treatment

Principal investigator

Christian Schultze-Florey

Efficacy and outcomes of allogeneic hematopoietic stem cell boost in adult patients with poor graft function

Retrospective Studies

Transplant Complications Working Party (TCWP)

Type of treatment

Principal investigator

Tatiana Rudakova

Outcomes of Allogeneic Hematopoietic Cell Transplantation from ≤8/10-HLA matched unrelated donor

Retrospective Studies

Transplant Complications Working Party (TCWP)

Type of treatment

Principal investigator

GVHD Prophylaxis with ATG or PTCy after alloSCT from unrelated donors

Retrospective Studies

Transplant Complications Working Party (TCWP)

Type of treatment

Principal investigator

ATG in the MSD setting - a real-world evidence study based on the EBMT Registry

Retrospective Studies

Transplant Complications Working Party (TCWP)

Type of treatment

Principal investigator

Agnieszka Piekarska

Survey on the use of SGLT2 inhibitors in cell therapy including autologous and allogeneic hematopoietic stem cell transplantation and CART cell therapy

Closed Survey/Study

Transplant Complications Working Party (TCWP)

Type of treatment

Principal investigator

Christian Schultze-Florey

How risky is a second allo? A retrospective analysis of treatment-related mortality in patients receiving allogeneic stem cell transplantation for the second time

Retrospective Studies

Transplant Complications Working Party (TCWP)

Type of treatment

Principal investigator

Potential factors influencing CAR-T cell manufacturing in terms of production failures and out of specification (OOS) products on behalf of EBMT - CTIWP

Closed Survey/Study

Cellular Therapy & Immunobiology Working Party (CTIWP)

Type of treatment

Principal investigator

Post-transplant cyclophosphamide as GvHD prophylaxis in patients with aplastic anemia with different donors: a comparative study of the SAAWP EBMT

Retrospective Studies

Bone marrow failure

Severe Aplastic Anaemia Working Party (SAAWP)

Type of treatment

Principal investigator

Defining protective immune cell subsets and subpopulations thresholds following allogeneic hematopoietic stem cell transplantation

Retrospective Studies

Cellular Therapy & Immunobiology Working Party (CTIWP)

Type of treatment

Principal investigator

Marina Cavazzana

Setting the stage for newborn screening and gene therapy: a disease-specific retrospective survey of FHL2 and 3

Retrospective Studies

Inherited disorders

Inborn Errors Working Party (IEWP)

Type of treatment

Principal investigator

Stephan Ehl, Despina Moshous, Claire Booth, Sujal Ghosh